The Investor portal is for our Novo Nordisk shareholders. By logging in, you can view your personal share information, register to receive Novo Nordisk Annual Reports and Annual General Meeting notifications, and change your contact information. Welcome Both a Danish and an English version of the...
Shareholders and financial analysts should address inquiries concerning Novo Nordisk and its business operations to the Investor Relations Officers.
Thank you. Welcome to this Novo Nordiskearnings callfor the first nine months of 2024. My name is Jacob Martin Wiborg Rode, and I'm the head of investor relations at Novo Nordisk. With me today, I have CEO of Novo Nordisk, Lars Fruergaard Jorgensen; executive vice president and head of...
Novo Nordisk, the $279 bn Danish multinational pharmaceutical company, was presented with the best overall investor relations (large cap) award, repeating its triumph from2021. Fellow Scandinavian Fredrik Berge, of Norwegian renewable energy infrastructure engineers Aker Solutions, was...
Investor Relations Contact Klaus Bülow DavidsenHead of Investor RelationsCorporate Vice PresidentNovo Allé2880 BagsværdDenmarkTel: +45 4442 3176Mobile: +45 3079 3176Fax: +45 4444 6626e-mail: klda@novonordisk.com About the company Novo Nordisk A/S is a global healthcare compa...
Sign up for the job agent service and receive emails when a matching job is available. We are always on the lookout for dedicated people for every part of our business at Novo Nordisk.
Welcome to Novo Nordisk's U.S. news and media hub. Here you can access our news releases, social media accounts, media contacts, sign up for email alerts, and more.
Novo Nordisk A/S (NVO) Q3 2022 Investor Conference Call November 3, 2022 9:15 AM ETCompany ParticipantsKarsten Munk Knudsen – Chief Financial OfficerCamilla...
Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark Telephone: +45 4444 8888 Internet: www.novonordisk.com CVR no: 24 25 67 90 Company announcement No 62 / 2023 About Ozempic® Once-weekly subcutaneous semaglutide is approved in 0.5, 1.0 and 2.0 mg doses under the ...
Shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) are under pressure at the time of writing after one of its long-time investors disclosed that it considerably reduced its stake in the company. The investor, Niall Gallagher, a European fund manager who runs GAM Investments, said the invest...